DK2880053T3 - Lindring af vævsskade og fibrose via anti-LTBP4-antistof - Google Patents
Lindring af vævsskade og fibrose via anti-LTBP4-antistof Download PDFInfo
- Publication number
- DK2880053T3 DK2880053T3 DK13835243.0T DK13835243T DK2880053T3 DK 2880053 T3 DK2880053 T3 DK 2880053T3 DK 13835243 T DK13835243 T DK 13835243T DK 2880053 T3 DK2880053 T3 DK 2880053T3
- Authority
- DK
- Denmark
- Prior art keywords
- relief
- tissue damage
- via anti
- fibrosis via
- ltbp4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678564P | 2012-08-01 | 2012-08-01 | |
PCT/US2013/053255 WO2014039189A1 (en) | 2012-08-01 | 2013-08-01 | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2880053T3 true DK2880053T3 (da) | 2020-05-11 |
Family
ID=50025687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13835243.0T DK2880053T3 (da) | 2012-08-01 | 2013-08-01 | Lindring af vævsskade og fibrose via anti-LTBP4-antistof |
Country Status (15)
Country | Link |
---|---|
US (9) | US9873739B2 (da) |
EP (2) | EP3711771A1 (da) |
AU (5) | AU2013313282B2 (da) |
CA (1) | CA2880649C (da) |
CY (1) | CY1123029T1 (da) |
DK (1) | DK2880053T3 (da) |
ES (1) | ES2791778T3 (da) |
HK (1) | HK1211307A1 (da) |
HR (1) | HRP20200818T1 (da) |
HU (1) | HUE049217T2 (da) |
PL (1) | PL2880053T3 (da) |
PT (1) | PT2880053T (da) |
RS (1) | RS60318B1 (da) |
SI (1) | SI2880053T1 (da) |
WO (1) | WO2014039189A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106470736B (zh) | 2014-05-13 | 2021-05-28 | 宾夕法尼亚州大学信托人 | 包括表达双抗体构建体的aav的组合物及其用途 |
WO2016054155A1 (en) * | 2014-09-30 | 2016-04-07 | Primegen Biotech, Llc. | Treatment of fibrosis using deep tissue heating and stem cell therapy |
KR20160101692A (ko) | 2015-02-17 | 2016-08-25 | 한국전자통신연구원 | 다채널 신호 처리 방법 및 상기 방법을 수행하는 다채널 신호 처리 장치 |
AU2016275909A1 (en) | 2015-05-13 | 2017-11-09 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
SG10201913833PA (en) | 2017-02-28 | 2020-03-30 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
MD3589730T2 (ro) | 2017-02-28 | 2024-04-30 | Univ Pennsylvania | Vector de virus adeno-asociat (AAV) de cladă F și utilizările acestuia |
US20220143136A1 (en) | 2018-12-21 | 2022-05-12 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5372807A (en) | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
CN100567322C (zh) | 1999-01-21 | 2009-12-09 | 梅塔莫菲克斯公司 | 抑制生长分化因子活性的多肽及表达该多肽的细胞 |
JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
US7368534B2 (en) | 2000-01-18 | 2008-05-06 | Orico Limited | Myostatin and mimetics thereof |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン(follistatin)ドメイン含有タンパク質 |
AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
MXPA05002968A (es) | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
DE60335915D1 (de) | 2002-12-20 | 2011-03-10 | Amgen Inc | Myostatin hemmende bindungsstoffe |
WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
EP3006039B1 (en) | 2004-03-02 | 2021-01-06 | Acceleron Pharma Inc. | Alk7 polypeptides for use in promoting fat loss |
US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
EP2332977B1 (en) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
AU2005280496B2 (en) | 2004-07-29 | 2009-10-08 | Schering-Plough Pty. Limited | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
US7807159B2 (en) | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
CA2731216A1 (en) * | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
FR2943249B1 (fr) | 2009-03-18 | 2011-08-12 | Genethon | Utilisation de la decorine pour augmenter la masse musculaire |
JP2012521199A (ja) | 2009-03-23 | 2012-09-13 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 免疫応答を調節するための化合物および方法 |
EP2427554B1 (en) | 2009-05-08 | 2016-11-16 | CuRNA, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
WO2012006181A2 (en) * | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
-
2013
- 2013-08-01 CA CA2880649A patent/CA2880649C/en active Active
- 2013-08-01 EP EP20152849.4A patent/EP3711771A1/en active Pending
- 2013-08-01 US US13/957,100 patent/US9873739B2/en active Active
- 2013-08-01 EP EP13835243.0A patent/EP2880053B8/en active Active
- 2013-08-01 SI SI201331718T patent/SI2880053T1/sl unknown
- 2013-08-01 AU AU2013313282A patent/AU2013313282B2/en active Active
- 2013-08-01 ES ES13835243T patent/ES2791778T3/es active Active
- 2013-08-01 HU HUE13835243A patent/HUE049217T2/hu unknown
- 2013-08-01 DK DK13835243.0T patent/DK2880053T3/da active
- 2013-08-01 PL PL13835243T patent/PL2880053T3/pl unknown
- 2013-08-01 PT PT138352430T patent/PT2880053T/pt unknown
- 2013-08-01 WO PCT/US2013/053255 patent/WO2014039189A1/en active Application Filing
- 2013-08-01 RS RS20200604A patent/RS60318B1/sr unknown
-
2015
- 2015-12-09 HK HK15112163.9A patent/HK1211307A1/xx unknown
-
2017
- 2017-12-28 US US15/857,122 patent/US20180134785A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200078A patent/AU2018200078A1/en not_active Abandoned
- 2018-09-05 US US16/122,333 patent/US20190002557A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/392,108 patent/US20190256589A1/en not_active Abandoned
- 2019-08-28 AU AU2019222850A patent/AU2019222850A1/en not_active Abandoned
- 2019-12-16 US US16/716,382 patent/US20200123247A1/en not_active Abandoned
-
2020
- 2020-05-20 HR HRP20200818TT patent/HRP20200818T1/hr unknown
- 2020-05-25 CY CY20201100496T patent/CY1123029T1/el unknown
- 2020-08-14 US US16/994,225 patent/US20200385457A1/en not_active Abandoned
-
2021
- 2021-02-08 AU AU2021200783A patent/AU2021200783B2/en active Active
- 2021-03-31 US US17/219,845 patent/US20210238274A1/en not_active Abandoned
- 2021-11-29 US US17/536,768 patent/US20220089717A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/811,233 patent/US20230235044A1/en not_active Abandoned
- 2022-11-15 AU AU2022271391A patent/AU2022271391A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2882496T3 (da) | Behandling og diagnosticering af melanom | |
DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
DK2850202T3 (da) | Fremgangsmåder og grupper | |
DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
BR112014001561A2 (pt) | região de mémoria temporária real variável e aparelho | |
DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
DK2855736T3 (da) | Elektrolysator og energisystem | |
DK2880053T3 (da) | Lindring af vævsskade og fibrose via anti-LTBP4-antistof | |
DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
DK2609956T3 (da) | Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde | |
DK2920313T3 (da) | Rekombinante adenovira og anvendelse deraf | |
DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
BR112012031446A2 (pt) | componentes e métodos para implantes | |
DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
DK2882441T3 (da) | Behandling af immunrelaterede og inflammatoriske sygdomme | |
DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
BR112012031130A2 (pt) | métodos e dispositivos para filtração | |
BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
DK3326642T3 (da) | Langtidsvirkende koagulationsfaktorer og brugen deraf | |
DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
DK2714055T3 (da) | Biokompatibelt materiale og anvendelser deraf |